Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant With/Without Triptorelin in Premenopausal Patients With HR+/HER2- Breast Cancer
NCT05982093Phase 2Recruiting
- Sponsor
- SOLTI
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in breast cancer, sponsored by SOLTI. Started Feb 2023; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05982093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05982093.